Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWight, Joel C-
dc.contributor.authorWai, Shin Hnin-
dc.contributor.authorShen, Edward-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorBerlangieri, Salvatore U-
dc.contributor.authorFancourt, Tineke-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorHannah, Anthony-
dc.contributor.authorLeung, Teresa-
dc.contributor.authorChong, Geoffrey-
dc.identifier.citationEuropean Journal of Haematology 2021; 107(4): 475-483en
dc.description.abstractInterim FDG-PET (iPET) in diffuse large B-cell lymphoma (DLBCL) is increasingly practiced and used in clinical trials to adapt further therapy. However, the optimum timing and methodology of iPET remains controversial. We retrospectively analysed the iPET results and outcomes of 200 DLBCL patients where FDG-PET was routinely performed at baseline, after 2 cycles (iPET2) and at completion of chemoimmunotherapy. iPET was also performed after 4 cycles (iPET4) where iPET2 was Deauville score (DS) ≥4. Scans were assessed by blinded expert lymphoma PET physicians for DS, maximum standard uptake value (SUVmax), total metabolic tumour volume (TMTV) and total lesion glycolysis (TLG). Treatment failure was defined as death, progression, or refractory disease. 95.5% of patients received R-CHOP. No baseline PET parameter predicted for EFS or OS independent of the NCCN-IPI. The multivariable analysis at iPET2 showed DS5 (19.5% of cases) predicted treatment failure (HR6.29, 95%CI 3.01 - 13.17, p<0.001) but DS4 was equivalent to DS1-3. At iPET4, ΔSUVmax <66% predicted treatment failure (HR 5.49, 95% CI 3.03-9.99, p<0.001). On multivariable analysis of all timepoints, high NCCN-IPI and DS5 at iPET2 were negative predictors for survival. These findings were independent of novel prognostic markers.en
dc.subjectInterim PETen
dc.titlePredicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean Journal of Haematologyen
dc.identifier.affiliationThe Northern Hospital, Melbourne, Australiaen
dc.identifier.affiliationThe University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationTownsville University Hospital, Townsville, Australiaen
dc.identifier.affiliationLa Trobe University, Melbourne, Australiaen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.pubmedid34240453-, Salvatore U
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Haematology- Newton-John Cancer Wellness and Research Centre- Imaging and Therapy- Haematology- Newton-John Cancer Wellness and Research Centre- Oncology- Pathology- Haematology- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Research Institute- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 21, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.